http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Jaejun Lee ),( Pil Soo Sung ),( Hyun Yang ),( Soon Kyu Lee ),( Sun Hong Yoo ),( Hae Lim Lee ),( Hee Yeon Kim ),( Jung-hyun Kwon ),( Hee Chul Nam ),( Sung Won Lee ),( Jeong Won Jang ),( Chang Wook Ki 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: In unresectable hepatocellular carcinoma (HCC), patients who are refractory to transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) have been considered suitable for multikinase inhibitor treatment, and sorafenib has traditionally been used as a salvage treatment option. Recently, lenvatinib was demonstrated to be non-inferior to sorafenib in a phase 3 randomized controlled trial. In this study, we aimed to investigate the efficacy and safety of lenvatinib as a salvage treatment for HCC after transarterial treatment. Methods: Between January 2019 and March 2020, all patients with confirmed intermediate-to-advanced HCC who were administered lenvatinib treatment after transarterial treatment in five Korean centers were retrospectively analyzed. We used overall survival (OS), progression free survival (PFS), objective response rate (ORR) and disease control rate (DCR) to evaluate efficacy of the treatment. Clinical parameters and outcomes after the introduction of lenvatinib were assessed. Results: We enrolled 38 unresectable HCC patients treated with lenvatinib after transarterial treatment. At the time of treatment initiation, 6 and 32 patients were classified as BCLC stage B and C, respectively. For the liver reserve, patients were classified as Child-Pugh class A (30 patients) or B (8 patients). Previous treatment included TACE for 35 patients, HAIC for 10 patients, and both TACE and HAIC for 7 patients. The median OS and PFS was 5.9 months (range, 0.7-13.2 months) and 3.9 months (range, 0.1-9.6 months), respectively. Sixteen among 38 patients were administered a 12-mg daily dose and 22 were administered an 8-mg daily dose. During the treatment, 10 of 38 (26.3%) patients had hand-foot syndrome (HFS); only 3 patients had grade 3 toxicity HFS. Among the patients, 6 (15.8%) had proteinuria and only one patient suffered grade 2 proteinuria while others had grade 1. In a best response evaluation, 5 patients exhibited a partial response (13.2%) and 12 patients had achieved stable disease (31.6%) according to the mRECIST criteria. Patients in the disease-controlled state (CR+PR+SD) showed superior OS (P=0.006) and PFS (P=0.003) to those with PD. Tumor size less than 5 cm was also associated with longer PFS (P=0.045). There was no statistically significant difference between OS and the number of prior transarterial treatments. Conclusions: Lenvatinib treatment is safe and efficacious after the failure of transarterial treatments in unresectable HCC. Change of treatment modality from loco-regional treatment to lenvatinib before the deterioration of liver function may achieve better survival outcomes in advanced HCC.
Plasma-Doped Si Nanosheets for Transistor and <i>p-n</i> Junction Application
Lee, Jaejun,Kwon, Juyoung,Seo, Dongjea,Na, Jukwan,Park, Sangwon,Lee, Hyo-Jung,Lee, Seung-Woo,Lee, Ki-Young,Park, Tae-Eon,Choi, Heon-Jin American Chemical Society 2019 ACS APPLIED MATERIALS & INTERFACES Vol.11 No.45
<P>Since the discovery of graphene, layered transition metal dichalcogenides (TMDs) have been considered promising materials for applications in various fields because of their fascinating structural features and physical properties. Doping in semiconducting TMDs is essential for their practical application. In this regard, two-dimensional (2D) Si materials have emerged as a key component of 2D electronic, optics, sensing, and spintronic devices because of their complementary metal-oxide-semiconductor (CMOS) compatibility, high-quality oxide formation, moderated bandgap, and well-established doping techniques. Here, we report the tuning of the electronic properties of Si nanosheets (NSs) using a plasma-doping technique. Using this doping process, we fabricated <I>p</I>-<I>n</I> homojunction diodes and transistors with Si NSs. The estimated high ON/OFF ratio of ∼10<SUP>6</SUP> and field-effect hole mobility of 329 cm<SUP>2</SUP> V<SUP>-1</SUP> s<SUP>-1</SUP> suggest a high crystal quality of the Si NSs. We also demonstrate vertically stacked heterostructured <I>p</I>-<I>n</I> junction diodes with MoS<SUB>2</SUB>, which exhibit rectifying properties and excellent light response.</P> [FIG OMISSION]</BR>
Soon Kyu Lee,Sung Won Lee,Hae Lim Lee,Hee Yeon Kim,Chang Wook Kim,Do Seon Song,U Im Chang,Jin Mo Yang,Sun Hong Yoo,Jung Hyun Kwon,Soon Woo Nam,Seok-Hwan Kim,Myeong Jun Song,Jaejun Lee,Hyun Yang,Si Hyu 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.6
Background/Aims : To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting. Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response. Results: Seventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved the end of treatment response, and 98.1% (202/206) achieved sustained virologic response at 12 weeks post-treatment (SVR12). According to liver function, the SVR12 rates were 99.3% (135/136) in chronic hepatitis, 96.4% (53/55) in compensated cirrhosis, and 100% (6/6) in decompensated cirrhosis. The SVR12 rates according to the genotype were 98.2% (167/170) for genotype 1 and 97.2% (35/36) for genotype 2. An 8-week LDV/SOF treatment in treatment-naïve chronic hepatitis patients with HCV RNA < 6,000,000 IU/mL at baseline resulted in 100% (23/23) SVR12 rates. Overall, LDV/SOF was tolerated well, with a 0.7% (2/273) discontinuation rate due to adverse events that were unrelated to LDV/SOF. Conclusions: LDV/SOF is effective and safe for treating HCV-infected Korean patients with high SVR12 rates.
무선 센서 네트워크를 이용한 농업 환경 모니터링 시스템 구현
이정민(Jeongmin Lee),한재준(Jaejun Han),이은애(Eunae Lee),이홍준(Hongjun Lee),김동식(Dong Sik Kim),정범진(Beom Jin Chung),손성용(Sung-Yong Son),구이란(Iran Koo),이형재(Hyung Jae Lee) 대한전자공학회 2015 대한전자공학회 학술대회 Vol.2015 No.11
In this paper, we developed a wireless sensor network system to monitor the temperature and humidity of the agriculture environment. In order to construct a low-cost and low-complexity system, a narrow-bandwidth communication based on 424MHz frequency band is considered while achieving reliable wireless links. The developed system is implemented in a farm for maesil, which is sort of plum. For a slope farm environment, the system can successfully gather the measured data.
On-Chip Supply Noise Suppression Technique Using Active Inductor
LEE, Jaejun,LEE, Sungho,NAM, Sangwook The Institute of Electronics, Information and Comm 2011 IEICE transactions on electronics Vol. No.
<P>This paper presents a circuit that improves supply noise rejection using an active inductor circuit. Compared to the conventional designs, the proposed supply noise suppression circuit has better characteristics such as low current consumption and small die size with noise rejection. The circuit was fabricated using 0.13µm UMC CMOS technology. The experimental results showed that the supply noise was suppressed by 61% with only an increase in size of 20.0µm × 2.5µm, and the current consumption was under 2mA.</P>